Changes of urinary immunity and microbiome after intravesical BCG therapy and their association with outcomes in NMIBC
Aim: Intravesical Bacillus Calmette–Guérin (BCG) is the standard therapy for non-muscle invasive bladder cancer (NMIBC); however, many patients experience recurrence or progression. We examined how urinary immune signals and the urinary microbiome change across BCG and are related to outcomes. Metho...
I tiakina i:
| Ngā kaituhi matua: | , , , , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Open Exploration Publishing Inc.
2026-04-01
|
| Rangatū: | Exploration of Targeted Anti-tumor Therapy |
| Ngā marau: | |
| Urunga tuihono: | https://www.explorationpub.com/uploads/Article/A1002365/1002365.pdf |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|